Pilocarpine modulates the cellular electrical properties of mammalian hearts by activating a cardiac M3 receptor and a K+ current.
1. Pilocarpine, a muscarinic acetylcholine receptor (mAChR) agonist, is widely used for treatment of xerostomia and glaucoma. It can also cause many other cellular responses by activating different subtypes of mAChRs in different tissues. However, the potential role of pilocarpine in modulating cardiac function remained unstudied. 2. We found that pilocarpine produced concentration-dependent (0.1-10 microM) decrease in sinus rhythm and action potential duration, and hyperpolarization of membrane potential in guinea-pig hearts. The effects were nearly completely reversed by 1 microM atropine or 2 nM 4DAMP methiodide (an M3-selective antagonist). 3. Patch-clamp recordings in dispersed myocytes from guinea-pig and canine atria revealed that pilocarpine induces a novel K+ current with delayed rectifying properties. The current was suppressed by low concentrations of M3-selective antagonists 4DAMP methiodide (2-10 nM), 4DAMP mustard (4-20 nM, an ackylating agent) and p-F-HHSiD (20-200 nM). Antagonists towards other subtypes (M1, M2 or M4) all failed to alter the current. 4. The affinity of pilocarpine (KD) at mAChRs derived from displacement binding of [3H]-NMS in the homogenates from dog atria was 2.2 microM (65% of the total binding) and that of 4DAMP methiodide was 2.8 nM (70% of total binding), consistent with the concentration of pilocarpine needed for the current induction and for the modulation of the cardiac electrical activity and the concentration of 4DAMP to block pilocarpine effects. 5. Our data indicate, for the first time, that pilocarpine modulates the cellular electrical properties of the hearts, likely by activating a K+ current mediated by M3 receptors.
Wang
H
H
Research Center, Montreal Heart Institute, Quebec, Canada.
Shi
H
H
Lu
Y
Y
Yang
B
B
Wang
Z
Z
D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D016275:Atrial Function; D001667:Binding, Competitive; D004285:Dogs; D004594:Electrophysiology; D005260:Female; D006168:Guinea Pigs; D006321:Heart / Q000187:drug effects* / Q000502:physiology*; D006325:Heart Atria / Q000166:cytology / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D008297:Male; D008564:Membrane Potentials / Q000187:drug effects; D008839:Microelectrodes; D018721:Muscarinic Agonists / Q000378:metabolism / Q000494:pharmacology*; D018727:Muscarinic Antagonists / Q000378:metabolism / Q000494:pharmacology; D009206:Myocardium / Q000378:metabolism; D019832:N-Methylscopolamine / Q000378:metabolism / Q000494:pharmacology; D010276:Parasympatholytics / Q000378:metabolism / Q000494:pharmacology; D010862:Pilocarpine / Q000378:metabolism / Q000494:pharmacology*; D010880:Piperidines / Q000378:metabolism / Q000494:pharmacology; D015221:Potassium Channels / Q000502:physiology*; D043587:Receptor, Muscarinic M3; D011976:Receptors, Muscarinic / Q000378:metabolism / Q000502:physiology*; D013997:Time Factors
D018721:Muscarinic Agonists; D018727:Muscarinic Antagonists; D010276:Parasympatholytics; D010880:Piperidines; D015221:Potassium Channels; D043587:Receptor, Muscarinic M3; D011976:Receptors, Muscarinic; D010862:Pilocarpine; C058297:4-fluorohexahydrosiladifenidol; C042375:4-diphenylacetoxy-1,1-dimethylpiperidinium; D019832:N-Methylscopolamine